Polyethyleneimine‐CpG Nanocomplex as an In Situ Vaccine for Boosting Anticancer Immunity in Melanoma
- 26 October 2020
- journal article
- research article
- Published by Wiley in Macromolecular Bioscience
- Vol. 21 (2) , e2000207
Abstract
Cancer immunotherapy is redefining the field of cancer therapy. However, current cancer immunotherapies are limited by insufficient immune activation, which results in low response rate. Herein, polyethyleneimine‐CpG nanocomplex (CpG@PEI) is reported as an in situ vaccine for boosting anticancer immunity in melanoma. CpG, a Toll‐like receptor (TLR) 9 agonist, can activate antigen‐presenting cells and increase the expression of costimulatory molecules, while PEI can help to enhance the stability and cellular internalization of CpG. It is proved that PEI loading can significantly enhance the cellular internalization and immune stimulation ability of CpG, and the CpG@PEI nanocomplex can effectively inhibit murine B16F10 melanoma growth after intratumoral injection. Further analysis reveals that this CpG@PEI nanocomplex therapy elicits both innate and adaptive immunity, with much increased natural killer (NK) cells and T cells infiltration in the tumor, as well as CD80 expression on the dendritic cells (DCs). This study will inspire more attempts in directly using single nanoparticle‐loaded pattern recognition receptor (PRR) agonists for cancer immunotherapy.Keywords
Funding Information
- National Natural Science Foundation of China (51673185, 51673189, 51973215, 51833010, 51520105004, 51829302)
- Jilin Provincial Scientific and Technological Development Program (20190103112JH)
This publication has 48 references indexed in Scilit:
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine, 2012
- Surface Charge Affects Cellular Uptake and Intracellular Trafficking of Chitosan-Based NanoparticlesBiomacromolecules, 2011
- CpG DNA as a vaccine adjuvantExpert Review of Vaccines, 2011
- Induction of Anti-Glioma Natural Killer Cell Response following Multiple Low-Dose Intracerebral CpG TherapyClinical Cancer Research, 2010
- The role of pattern-recognition receptors in innate immunity: update on Toll-like receptorsNature Immunology, 2010
- Infection-mimicking materials to program dendritic cells in situNature Materials, 2009
- Intracellular pattern recognition receptors in the host responseNature, 2006
- Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cellsNature, 2006
- Necessity of Oligonucleotide Aggregation for Toll-like Receptor 9 ActivationJournal of Biological Chemistry, 2004
- Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells.Journal of Experimental Medicine, 1993